Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
Tel: 317-276-2000
Website: http://www.lilly.com/
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2392 articles with Eli Lilly and Company
-
Lilly Declares Fourth-Quarter 2019 Dividend
10/21/2019
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2019 of $0.645 per share on outstanding common stock.
-
Clinical Catch-Up: October 14-18
10/21/2019
Last week was busy for clinical trial news. Here’s a look. -
After Cancer Drug Fails Pancreatic Cancer Trial, Lilly Plans to Continue Studies in Lung and Rena...
10/17/2019
Lilly picked up pegilodecakin, an immunotherapy that stimulates the body’s immune system and expands tumor-attacking T-cells, when it acquired ARMO BioSciences in June 2018 for $1.6 billion. -
Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival
10/16/2019
Eli Lilly and Company announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX compared to FOLFOX alone in patients with metastatic pancreatic cancer whose disease had progressed during or following a first-line gemcitabine-containing regimen.
-
Eli Lilly to Present Key Findings in Implementing Pelican BioThermal, LLC Multi-Use Shippers at the Cold Chain Global Forum on October 17, 2019
10/16/2019
Presentation will highlight the critical value of having a quality-based refurbishment program for multi-use shippers
-
PhRMA Appoints New Leadership to Board of Directors
10/16/2019
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) appointed new leadership to its board of directors.
-
The facility is expected to close by the end of 2020, affecting 270 staffers, with 80 possible redundancies.
-
The U.S. Food and Drug Administration approved Eli Lilly's Reyvow (lasmiditan) for the acute treatment of migraines.
-
Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
10/12/2019
Taltz is the first and only IL-17A inhibitor with published clinical trial results in pediatric patients with moderate to severe plaque psoriasis
-
Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
10/11/2019
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment of migraine, with or without aura, in adults
-
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
-
New Head-to-Head Data Show TALTZ® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis - Oct. 10, 2019
10/10/2019
TALTZ met the primary endpoint of the IXORA-R study, with 41.3 percent of patients taking TALTZ achieving complete skin clearance as measured by PASI 100 at Week 12 versus 24.9 percent of patients taking TREMFYA
-
Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
10/8/2019
Research from Taltz®, Olumiant® and mirikizumab highlight the impact Lilly's medicines may have for patients around the world
-
Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology
10/7/2019
CYRAMZA, in combination with erlotinib, significantly delayed disease progression in previously untreated patients with metastatic non-small cell lung cancer whose tumors have activating EGFR mutations
-
It was another busy week for clinical trials. Here’s a look.
-
New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis
10/3/2019
Taltz met the primary endpoint of the IXORA-R study, with 41.3 percent of patients taking Taltz achieving complete skin clearance as measured by PASI 100 at Week 12 versus 24.9 percent of patients taking TREMFYA
-
Lilly Announces Voluntary Delisting from Euronext Paris
10/3/2019
Eli Lilly and Company (NYSE: LLY) announced today that it has requested the delisting of its shares (ISIN US5324571083) ("Lilly Shares") from Euronext Paris due to the very low trading volume, costs and administrative requirements related to its secondary listing on Euronext Paris
-
In 2017, a lawsuit was filed alleging that Eli Lilly and Bayer, as well as other companies, attempted to use the free nursing services as a way to boost sales of diabetes drugs, such as Humalog and Humulin, as well as other drugs.
-
Lilly Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement
10/2/2019
Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
-
Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case
9/30/2019
The payment of USD 14.3 million corresponds to the USD 11.6 million in damages plus interest awarded to Adocia in August 2018 by an American Arbitration Association Panel presiding over Adocia’s arbitration claims against Eli Lilly